Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris and Avastin in refractory CD-30 positive germ cell tumors
NCT02988843Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2017
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in germ cell tumor (GCT), sponsored by Masonic Cancer Center. Primary endpoint: Objective Response Rate at 1 year. Started Mar 2017; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT02988843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988843.